Clinical Trial Update: Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial assessing the long-term safety and efficacy of etelcalcetide in secondary hyperparathyroidism has been terminated. Results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• Parsabiv (etelcalcetide)

Snippet

Sponsor: KAI Pharmaceuticals | Conditions: Secondary Hyperparathyroidism | Phase 2 | Status: TERMINATED | Results posted: 2017-04-13